POLICY BRIEF: The INSULIN Act — Higher insulin prices and less innovation

Congressional Democrats are mounting renewed efforts to impose drug price controls. One effort is contained in a new reconciliation proposal. Another, separate measure specifically addresses insulin prices in the INSULIN Act introduced by Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME). This policy brief examines the INSULIN Act and argues that the proposal will harm patients through higher insulin prices and reduced innovation while raising health insurance premiums and government spending.

Download the full brief here.

Link to HTML version.

© Paragon Health Institute 2022. All Rights Reserved.

Paragon Health Institute (PHI) is a non-partisan, not-for-profit policy research institute. Any views, beliefs, or opinions expressed by PHI’s Public Advisors are those of its Advisors and do not necessarily reflect the official policies or positions of PHI or its employees. Any views, beliefs, or opinions expressed by PHI or its employees belong solely to PHI and do not necessarily reflect those of PHI’s Public Advisors.